映恩生物-亚洲医疗行业考察要点

Duality Bio's collaboration with BioNTech (BNT) provides a unique structure: retaining China rights for ADC programs while granting ex-China rights to BNT, which also covers ex- China development costs. For B7-H3 ADC, Duality holds an option to co-fund 50% of U.S. development, offering significant upside. This partnership enables Duality to leverage BNT's global infrastructure and BMS's IO expertise while maintaining strategic control in China and optionality in key global markets. B7-H3 and Trop-2 ADCs Pos ...